Drug repurposing: Mining protozoan proteomes for targets of known bioactive compounds

Journal of the American Medical Informatics Association

Volumn 21, Issue 2, 2014, Pages 238-244

  Sateriale, Adam ^a   Bessoff, Kovi ^a   Sarkar, Indra Neil ^a   Huston, Christopher D ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTATIONAL BIOLOGY; DRUG REPOSITIONING; DRUG THERAPY; PARASITOLOGY; PROTEOMICS;

ANIMALS; ANTIPARASITIC AGENTS; COMPUTER SIMULATION; CRYPTOSPORIDIUM PARVUM; DATABASES, PROTEIN; DRUG REPOSITIONING; HUMANS; PARASITES; PARASITIC DISEASES; PARASITIC SENSITIVITY TESTS; PROTEOME;

EID: 84894071251     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2013-001700     Document Type: Article

References (32)

1. Sardana D, Zhu C, Zhang M, et al. Drug repositioning for orphan diseases. Brief Bioinform 2011;12:346-56.
2. Strauss S. Pharma embraces open source models. Nat Biotechnol 2010;28:631-4.
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
4. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83.
5. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009;22:119-25.
6. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-6.
7. Graul AI, Sorbera L, Pina P, et al. The year's new drugs & biologics-2009. Drug News Perspect 2010;23:7-36.
8. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007;152:9-20.
9. Wang S, Zaharevitz DW, Sharma R, et al. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies. J Med Chem 1994;37:4479-89.
10. Nicklaus MC, Neamati N, Hong H, et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem 1997;40:920-9.
11. Carlson HA, Masukawa KM, Rubins K, et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem 2000;43:2100-14.
12. Debnath AK. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J Med Chem 2003;46:4501-15.
13. von Eichborn J, Murgueitio MS, Dunkel M, et al. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2011;39(Database issue): D1060-6.
14. Cockell SJ, Weile J, Lord P, et al. An integrated dataset for in silico drug discovery. J Integr Bioinform 2010;7:116.
15. Andronis C, Sharma A, Virvilis V, et al. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011;12:357-68.
16. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40(Database issue):D1100-7.
17. Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 2009;37(Web server issue):W623-33.
18. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011;39(Database issue):D1035-41.
19. Bessoff K, Sateriale A, Lee KK, et al. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother 2013;57:1804-14.
20. Yu YK, Altschul SF. The construction of amino acid substitution matrices for the comparison of proteins with non-standard compositions. Bioinformatics 2005;21:902-11.
21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
22. Abubakar I, Aliyu SH, Arumugam C, et al. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol 2007;63:387-93.
23. Rossignol JF, Hidalgo H, Feregrino M, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998;92:663-6.
24. Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002;360:1375-80.
25. Schneider G. Neural networks are useful tools for drug design. Neural Netw 2000;13:15-16.
26. Lipkin MJ, Stevens AP, Livingstone DJ, et al. How large does a compound screening collection need to be? Comb Chem High Throughput Screen 2008;11:482-93.
27. Wetzel S, Klein K, Renner S, et al. Interactive exploration of chemical space with Scaffold Hunter. Nat Chem Biol 2009;5:581-3.
28. Schonian G, Schweynoch C, Zlateva K, et al. Identification and determination of the relationships of species and strains within the genus Leishmania using single primers in the polymerase chain reaction. Mol Biochem Parasitol 1996;77:19-29.
29. Croan DG, Morrison DA, Ellis JT. Evolution of the genus Leishmania revealed by comparison of DNA and RNA polymerase gene sequences. Mol Biochem Parasitol 1997;89:149-59.
30. Meng J, Mangat SS, Grudzinski IP, et al. Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact 1998;14:209-19.
31. Hossain M, Giri P, Kumar GS. DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study. DNA Cell Biol 2008;27:81-90.
32. Spitzer M, Griffiths E, Blakely KM, et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 2011;7:499.